The investigational drug dimebon failed to show any benefit over placebo for patients with mild to moderate Alzheimer’s disease on any of the efficacy end points in a 6-month, phase III trial, drug manufacturers Medivation Inc. and Pfizer Inc. announced.Although the tolerability of the drug was confirmed in the efficacy study, called CONNECTION, and in a separate phase III safety and tolerability study, the results put the future of the drug in doubt.Dr. Marwan N. Sabbagh said that he and other...

SAVANNAH, Georgia (EGMN) – Deep brain stimulation may have potential for treating geriatric psychiatric disorders, particularly treatment-resistant depression and obsessive-compulsive disorder.Deep brain stimulation (DBS), already shown to be an effective therapy for Parkinson’s disease and essential tremor, may hold promise for treatment of geriatric psychiatric disorders, Dr. Paul Holtzheimer said in a symposium on neuromodulation therapies at the annual meeting of the American Association...